small molecule

ELIQUIS SPRINKLE

APIXABAN

Loss of exclusivityMay 2041latest FDA-listed patent expiry

CompanyBRISTOL MYERS SQUIBB CO

Drug detail

Brand name	ELIQUIS SPRINKLE
Active ingredient	APIXABAN
Strength	0.15MG
Dosage form	FOR SUSPENSION
Route	ORAL
Modality	Small molecule
FDA approval	April 2025
Marketing status	RX

Listed patents

Patent	Expires	Type
11896586*PED	May 2041	—
11896586	November 2040	product
6967208*PED	May 2027	—
6967208	November 2026	substance, product

Regulatory exclusivity

Code	Expires
PED	October 2028
NP	April 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from BRISTOL MYERS SQUIBB CO